DETERMINANTS OF SERUMS CAPACITY OF ACCEPT CHOLESTEROL

血清接受胆固醇能力的决定因素

• 批准号: 2445039
• 负责人: MARGARITA E DE LA LLERA-MOYA
• 金额: $ 8.82万
• 依托单位: ALLEGHENY UNIVERSITY OF HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2445039
• 关键词: blood chemistry; blood disorder; blood lipoprotein metabolism; blood lipoprotein transport; cholesterol; high density lipoproteins; human subject; human tissue; intermolecular interaction; laboratory mouse; lipid transport; membrane model; phosphatidylcholines; radiotracer; tissue /cell culture

Dr. M. E. De La Llera-Moya was born in Cuba and emigrated to this country in 1960. She is a USA citizen. She is a competent scientist and has receive all her scientific training in the States. Dr. Moya has recently moved into an academic research position in the Biochemistry Department at the Allegheny University of the Health Sciences, MCP Hohneman School of Medicine after spending some time directing a specialized clinical lipid laboratory to support a Lipid Disorders Clinic at the Medical College of Pennsylvania Hospital. Dr. Moya has developed an interesting experimental system to investigate the serum factors that affect cellular cholesterol afflux with specific emphasis on the role HDL has in this process. This application centers on further development of this potentially important methodology. Although it is currently thought that the HDL lipoprotein fraction plays a crucial role in the transport of excess tissue cholesterol to the liver for excretion, HDL are heterogeneous and the specific fraction of HDL involved in this important function has not been identified. In addition it is not clear what serum factors interact with HDL to facilitate its cholesterol-transport function. This incomplete understanding of HDL function has important clinical implications since, although high levels of HDL are linked to decreased risk of CAD, not all individuals with abnormally low HDL are equally threatened. Moreover it is not at all clear what are the appropriate therapeutic interventions to modulate HDL levels and reduce CAD risk. Dr. Moya's present appointment in the Biochemistry Department at MCP HSM gives her the best possible support for her work since her sponsor and the other senior members in the department have an established record of successful research in the area of HDL metabolism. Thus all the pertinent equipment, methodology and the expertise will be easily accessible to insure fruitful completion of the work in this application.

M.E. De La Llera-Moya 博士出生于古巴并移民到这个国家 1960 年。她是美国公民。 她是一位有能力的科学家并拥有 在美国接受所有科学培训。 莫亚博士最近 进入生物化学系从事学术研究工作 阿勒格尼健康科学大学 MCP Hohneman 学院 花了一些时间指导专门的临床脂质后的医学 实验室支持医学院的脂质紊乱诊所 宾夕法尼亚医院。 莫亚博士开发了一个有趣的实验 研究影响细胞胆固醇的血清因素的系统 afflux 特别强调 HDL 在这一过程中的作用。 这 应用程序集中于进一步开发这一潜在的重要 方法论。 尽管目前认为 HDL 脂蛋白 分数在多余组织的运输中起着至关重要的作用 胆固醇到肝脏排泄，HDL 是异质的， 参与这一重要功能的 HDL 的具体部分尚未确定 确定。 此外，尚不清楚哪些血清因子与 HDL 促进其胆固醇转运功能。 这个不完整的 了解 HDL 功能具有重要的临床意义，因为 虽然高水平的 HDL 与降低 CAD 风险有关，但并非所有 HDL 异常低的个体同样受到威胁。 而且它 根本不清楚什么是适当的治疗干预措施 调节 HDL 水平并降低 CAD 风险。 Moya 博士目前的任命 MCP HSM 生物化学系的工作为她提供了最好的机会 自从她的赞助人和其他高级成员以来对她工作的支持 部门在该领域拥有成功研究的既定记录 HDL 代谢。 因此，所有相关的设备、方法和 将很容易获得专业知识，以确保圆满完成 在此应用程序中工作。